FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $21.7 million versus the consensus estimate of $21.24 million.
GUIDANCE:
Corcept Therapeutics sees Q4 2016 revenue of $79-82 million, versus the consensus of... More

